These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27203646)

  • 1. Risk of stent thrombosis with bioresorbable vascular scaffolds.
    Shah R; Ramos-Bondy B; Mizeracki A
    Lancet; 2016 May; 387(10031):1903. PubMed ID: 27203646
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of stent thrombosis with bioresorbable vascular scaffolds - Authors' reply.
    Cassese S; Kastrati A
    Lancet; 2016 May; 387(10031):1904. PubMed ID: 27203648
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect on death of scaffold thrombosis versus stent thrombosis.
    Lafont A; Mennuni MG
    Lancet; 2016 May; 387(10034):2198. PubMed ID: 27302028
    [No Abstract]   [Full Text] [Related]  

  • 4. The clinical challenge of disappearing stents.
    Finn AV; Virmani R
    Lancet; 2016 Feb; 387(10018):510-512. PubMed ID: 26597772
    [No Abstract]   [Full Text] [Related]  

  • 5. Bioresorbable Scaffolds for Coronary Artery Disease.
    Nathan A; Kobayashi T; Kolansky DM; Wilensky RL; Giri J
    Curr Cardiol Rep; 2017 Jan; 19(1):5. PubMed ID: 28108898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.
    Ellis SG; Kereiakes DJ; Metzger DC; Caputo RP; Rizik DG; Teirstein PS; Litt MR; Kini A; Kabour A; Marx SO; Popma JJ; McGreevy R; Zhang Z; Simonton C; Stone GW;
    N Engl J Med; 2015 Nov; 373(20):1905-15. PubMed ID: 26457558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial.
    Chevalier B; Onuma Y; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; Smits PC; Kumar R; Wasungu L; Serruys PW
    EuroIntervention; 2016 Oct; 12(9):1102-1107. PubMed ID: 27564310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioresorbable Vascular Scaffolds--Will Promise Become Reality?
    Byrne RA
    N Engl J Med; 2015 Nov; 373(20):1969-71. PubMed ID: 26457446
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial.
    Arroyo D; Gendre G; Schukraft S; Kallinikou Z; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Togni M; Cook S; Puricel S
    Int J Cardiol; 2017 Sep; 243():121-125. PubMed ID: 28576627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodegradable stents: the golden future of angioplasty?
    Di Mario C; Caiazzo G
    Lancet; 2015 Jan; 385(9962):10-12. PubMed ID: 25230592
    [No Abstract]   [Full Text] [Related]  

  • 12. Coronary artery aneurysms formation within Everolimus-eluting stents and bioresorbable vascular scaffolds.
    Lee WC; Chung WJ; Fang HY; Wu CJ
    Int J Cardiol; 2016 Mar; 206():58-60. PubMed ID: 26774833
    [No Abstract]   [Full Text] [Related]  

  • 13. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.
    Montone RA; Niccoli G; De Marco F; Minelli S; D'Ascenzo F; Testa L; Bedogni F; Crea F
    Circulation; 2017 May; 135(22):2145-2154. PubMed ID: 28559495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis.
    Zhang XL; Zhu L; Wei ZH; Zhu QQ; Qiao JZ; Dai Q; Huang W; Li XH; Xie J; Kang LN; Wang L; Xu B
    Ann Intern Med; 2016 Jun; 164(11):752-63. PubMed ID: 27042809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential aspects between cobalt-chromium everolimus drug-eluting stent and Absorb everolimus bioresorbable vascular scaffold: from bench to clinical use.
    Sotomi Y; Suwannasom P; Tenekecioglu E; Tateishi H; Abdelghani M; Serruys PW; Onuma Y
    Expert Rev Cardiovasc Ther; 2015 Oct; 13(10):1127-45. PubMed ID: 26401921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.
    de Winter RJ; Katagiri Y; Asano T; Milewski KP; Lurz P; Buszman P; Jessurun GAJ; Koch KT; Troquay RPT; Hamer BJB; Ophuis TO; Wöhrle J; Wyderka R; Cayla G; Hofma SH; Levesque S; Żurakowski A; Fischer D; Kośmider M; Goube P; Arkenbout EK; Noutsias M; Ferrari MW; Onuma Y; Wijns W; Serruys PW
    Lancet; 2018 Feb; 391(10119):431-440. PubMed ID: 29203070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes After Implantation of Overlapping Bioresorbable Scaffolds vs New Generation Everolimus Eluting Stents.
    Panoulas VF; Kawamoto H; Sato K; Miyazaki T; Naganuma T; Sticchi A; Latib A; Colombo A
    Rev Esp Cardiol (Engl Ed); 2016 Dec; 69(12):1135-1143. PubMed ID: 27264490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.